Lin Qiu

Lin Qiu

Auto-generated profile, based on publicly available information

Lin Qiu

Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2022 in Radiology
Verified
Journal Article
Closed access
LLLianjun Lan
Lianjun Lan
SZShumao Zhang
Shumao Zhang
TXTingting Xu
Tingting Xu
HLHuipan Liu
Huipan Liu
WWWei Wang
Wei Wang
LQLin Qiu
Lin Qiu
Gallium 68–labeled fibroblast-activation protein inhibitor PET/CT was superior to fluorine 18 fluorodeoxyglucose PET/CT for the staging of biliary tract cancer. Background Gallium 68–labeled fibroblast-activation protein inhibitor (68Ga-FAPI), an imaging agent for detecting tumors, represents a promising alternative to fluorine 18 fluorodeoxyglucose (18F-F...

1 July 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
SZShumao Zhang
Shumao Zhang
WWWei Wang
Wei Wang
TXTingting Xu
Tingting Xu
HDHaoyuan Ding
Haoyuan Ding
YLYi Li
Yi Li
LQLin Qiu
Lin Qiu
Purpose: This study aimed to compare the potential diagnostic efficacy of gallium68-fibroblast-activation protein inhibitor ([68Ga]Ga-FAPI-04) and fluorine18-fluorodeoxyglucose ([18F]-FDG) positron emission tomography-computed tomography (PET/CT) for primary tumors, lymph nodes, and distant metastatic lesions of gastric cancer (GC), and to explore the effects of [68Ga]Ga-FAPI-04 and [18F]-FDG on tumor staging and restaging in GC.Methods: This single-center retrospective study (NCT2100044131) was conducted at the Affiliated Hospital of the Southwest Medical University between June 2020 and December 2021. Images of patients with GC who were pathologically confirmed and underwent contemporaneous [18F]-FDG and [68Ga]Ga-FAPI-04 PET/CT within 1 week were analyzed. The diagnostic efficacy of [68Ga]Ga-FAPI-04 PET/CT and [18F]-FDG PET/CT for TNM staging of GC was compared using McNemar test. The maximum standard uptake value (SUVmax) of each lesion in the two imaging types was compared using the Mann-Whitney U test.Results: In total, 25 patients with GC (mean age, 56 ± 12 years) were evaluated. [68Ga]Ga-FAPI-04 PET/CT exhibited higher sensitivity compared to [18F]-FDG PET/CT for detecting primary tumors (18/19 [94.74%] vs. 13/19 [68.42%], χ2 = 6.866, P < 0.01), lymph node metastasis (75/77 [97.40%] vs. 32/77 [41.56%], χ2 = 2.888, P =0.089), and distant metastases (275/283 [97.17%] vs. 122/283 [43.11%], χ2 = 11.858, P < 0.01). [68Ga]Ga-FAPI-04 accumulation was significantly higher than that of [18F]FDG in tumors (median SUVmax, 10.28 vs 3.20; U=59.00, P < 0.01), lymph node metastasis metastases (median SUVmax, 9.20 vs 3.15; U=53.50, P < 0.01), and distant metastases (median SUVmax, 8.00 vs 4.20; U=200.00, P < 0.01). Compared to [18F]-FDG PET/CT, [68Ga]Ga-FAPI-04 PET/CT resulted in new oncological findings in 14/25 patients and corrected tumor staging or restaging in 7/25 patients.Conclusion: Our preliminary results regarding the impact of [68Ga]Ga-FAPI-04 PET/CT on tumor staging highlight the potential of this approach for increasing the accuracy of GC diagnosis, which may facilitate treatment decision-making.

26 March 2023 in Clinical Nuclear Medicine
Verified
Journal Article
Closed access
LQLin Qiu
Lin Qiu
YWYingwei Mm Wang
Yingwei Mm Wang
HLHanxiang Mm Liu
Hanxiang Mm Liu
QWQixin Mm Wang
Qixin Mm Wang
LCLin Mm Chen
Lin Mm Chen
YCYue Chen
Yue Chen
Purpose: We designed and synthesized a novel theranostic bisphosphonate radiopharmaceutical (68Ga- or 177Lu-labeled DOTA-ibandronic acid [68Ga/177Lu-DOTA-IBA]) for bone metastasis. In this study, the dosimetry, safety, and efficacy of 68Ga/177Lu-DOTA-IBA as a theranostic radiopharmaceutical for bone metastases were evaluated in patients with malignancy based on 68Ga- and 177Lu-DOTA-IBA images, blood samples, and dosimetric analysis. Patients and Methods: Eighteen patients with bone metastasis and progression under conventional therapies were included in this study. Baseline 99mTc-MDP SPECT and 68Ga-DOTA-IBA PET/CT were performed for comparative purposes within 3 days. After receiving 891.5 ± 301.3 MBq 177Lu-DOTA-IBA, serial 177Lu-DOTA-IBA SPECT bone scan was performed over 14 days. Dosimetric evaluation was performed for main organs and tumor lesions. Safety was assessed by blood biomarkers. Karnofsky Performance Status, pain score, and follow-up 68Ga-DOTA-IBA PET/CT were performed for response evaluation. Results: Baseline 68Ga-DOTA-IBA PET demonstrated a higher efficacy for detecting bone metastases compared with 99mTc-MDP SPECT. The time-activity curves showed fast uptake and high retention of 177Lu-DOTA-IBA in bone metastases (24 hours: 9.43 ± 2.75 %IA; 14 days: 5.45 ± 2.52 %IA). Liver, kidneys, and red marrow time-activity curves revealed a low uptake and fast clearance. The radiation-absorbed dose in bone metastasis lesions (6.40 ± 2.13 Gy/GBq) was significantly higher than that in red marrow (0.47 ± 0.19 Gy/GBq), kidneys (0.56 ± 0.19 Gy/GBq), or liver (0.28 ± 0.07 Gy/GBq), with all P’s < 0.001. Compared with baseline level, only one patient developed new grade 1 leukopenia (toxicity rate, 6%). The 177Lu-DOTA-IBA therapy had no statistically significant effect on bone marrow hematopoietic function, liver function, and kidney function at any follow-up visit. Bone pain palliation was achieved in 82% (14/17) of patients. The 8-week follow-up 68Ga-DOTA-IBA PET/CT demonstrated partial response in 3 patients, disease progression in 1 patient, and stable disease in 14 patients. Conclusions: 68Ga/177Lu-DOTA-IBA provides a set of potential theranostic radiopharmaceuticals and may have a good prospect for the management of bone metastasis.

14 December 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
YWYingwei Wang
Yingwei Wang
QWQixin Wang
Qixin Wang
HMHongfeng Meng
Hongfeng Meng
JYJian Yang
Jian Yang
HLHanxiang Liu
Hanxiang Liu
YCYue Chen
Yue Chen
Purpose: In this study, DOTA-IBA was radiolabeled with 68Ga and we determined the optimum labelling conditions and assessed the biological properties of 68Ga-DOTA-IBA. We investigated the biodistribution of 68Ga-DOTA-IBA in normal animals and undertook PET/CT imaging in humans. Finally, we explored the feasibility 68Ga-DOTA-IBA as a bone imaging agent and demonstrated its potential for the therapeutic release of 177Lu/225Ac-DOTA-IBA.Methods: The controlled variables method was used to assess the impact of variables on the radiochemical purity of 68Ga-DOTA-IBA. The biological properties of 68Ga-DOTA-IBA were investigated.68Ga-DOTA-IBA micro-PET/CT imaging was performed on animals. Volunteers were recruited for 68Ga-DOTA-IBA imaging and data were compared to 99mTc-MDP imaging studies to calculate the target to non-target ratio (T/NT) of the lesions.Results: The prepared 68Ga-DOTA-IBA had a radiochemical purity of >97% and demonstrated good biological properties with a good safety profile in normal mice. PET/CT imaging of the animals showed rapid blood clearance with high contrast between the bone and stroma. Human imaging showed that 68Ga-DOTA-IBA could detect more lesions compared to 99mTc-MDP and had a higher targeted to untargeted ratio.Conclusions: 68Ga-DOTA-IBA is an osteophilic radiopharmaceutical that can be synthesized using a simple labelling method. 68Ga-DOTA-IBA has high radiochemical purity and is stable in vitro stability. It is rapidly cleared from the blood, has low toxicity and has strong targeting to the bone with long retention times. We also found that it is rapidly cleared in non-target tissues and has high contrast on whole-body bone imaging. 68Ga-DOTA-IBA PET/CT has potential as a novel bone imaging bone modality in patients with metastatic disease.

15 December 2021 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
HLHanxiang Liu
Hanxiang Liu
MHMei Hu
Mei Hu
JDJia Deng
Jia Deng
YZYan Zhao
Yan Zhao
DPDengsai Peng
Dengsai Peng
LQLin Qiu
Lin Qiu

25 August 2019 in Contrast Media & Molecular Imaging
Verified
Journal Article
Open access
PDF file
LQLin Qiu
Lin Qiu
WMWujian Mao
Wujian Mao
HYHongyan Yin
Hongyan Yin
HTHui Tan
Hui Tan
Cheng DengfengCheng Dengfeng
Cheng Dengfeng
HSHongcheng Shi
Hongcheng Shi
The exceptional speed and biorthogonality of the inverse electron-demand Diels–Alder (IEDDA) click chemistry between 1,2,4,5-tetrazines and strained alkene dienophiles have made it promising in the realm of pretargeted imaging and therapy. During the past 10 years, the IEDDA-pretargeted strategies have been tested and have already proven capable of producing images with high tumor-to-background ratios and improving therapeutic effect. This review will focus on recent applications of click chemistry ligations in the pretargeted imaging studies of single photon emission computed tomography (SPECT), positron emission tomography (PET), and pretargeted radioimmunotherapy investigations. Additionally, the influence factors of stability, reactivity, and pharmacokinetic properties of TCO tag modified immunoconjugates and radiolabeled Tz derivatives were also summarized in this article, which should be carefully considered in the system design in order to develop a successful pretargeted methodology. We hope that this review will not only equip readers with a knowledge of pretargeted methodology based on IEDDA click chemistry but also inspire synthetic chemists and radiochemists to develop pretargeted radiopharmaceutical components in a more innovative way with various influence factors considered.